Article may be outdated

This article is 8 days old. Some details may have changed since publication.

Contagion Live·3 min read·medium

Is the mRNA Influenza Vaccine More Efficacious in Older Adults?

J
John Parkinson, Deborah Fuller, PhD
Is the mRNA Influenza Vaccine More Efficacious in Older Adults?
✦AI Summary

A study published in the New England Journal of Medicine indicates that the mRNA-1010 influenza vaccine is more effective than standard vaccines for adults aged 50 and older. The data shows higher efficacy rates in older demographics, who face a disproportionately high risk of severe illness and death from the flu.

Why it matters

Improving vaccine efficacy for older adults is critical for reducing the significant annual burden of influenza-related hospitalizations and mortality.

✦Dive DeeperCreate a free account to unlock

In a study published earlier this year in the New England Journal of Medicine, the mRNA-1010 mRNA influenza vaccine prevented disease in adults 50 years and older more effectively than standard vaccines. Specifically, data showed that confirmed influenza-like illness occurred in 2.0% of mRNA-1010 vaccine recipients and 2.8% of comparator recipients, with a relative vaccine efficacy of 26.6% (95% CI, 16.7 to 35.4). And in adults 65 and older, the results were slightly better, with a relative vaccine efficacy of 27.4%.¹

“mRNA-1010 was superior to standard-dose licensed vaccines for prevention of RT-PCR–confirmed, protocol-defined influenza-like illness in adults 50 years of age or older,” the authors concluded.

Influenza Disease Burden in Older Adults

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →
healthscience
✦

Get smarter about the news

Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.

Create free account

Already have an account? Sign in